Literature DB >> 2018160

The assessment and treatment of performance anxiety in musicians.

D B Clark1, W S Agras.   

Abstract

OBJECTIVE: Performance anxiety in musicians may be severe enough to require intervention but has been the subject of relatively little clinical research. The authors' objectives were to describe the results of a comprehensive clinical and laboratory assessment and to perform a double-blind, placebo-controlled study comparing buspirone, cognitive-behavior therapy, and the combination of these treatments for performance anxiety.
METHOD: Ninety-four subjects were recruited by mass media announcements and were seen in a university-based outpatient psychiatric clinic. Assessments were 1) questionnaires for all 94 subjects, 2) diagnostic interview of 50 subjects, and 3) laboratory performance of 34 subjects. Treatment conditions were 1) 6 weeks of buspirone, 2) 6 weeks of placebo, 3) a five-session, group cognitive-behavior therapy program with buspirone, or 4) the cognitive-behavior therapy program with placebo. Treatment outcome measures included subjective anxiety ratings and heart rate measures during a laboratory performance, a questionnaire measure of performance confidence, and a blind rating of musical performance quality.
RESULTS: All subjects fulfilled criteria for DSM-III-R social phobia. Of the 15 full-time professional musicians, ten had tried propranolol and three had stopped performing. Most of the subjects had substantial anxiety and heart rate increases during laboratory speech and musical performances. Cognitive-behavior therapy resulted in statistically significant reductions in subjective anxiety, improved quality of musical performance, and improved performance confidence. Buspirone was not an effective treatment.
CONCLUSIONS: Cognitive-behavior therapy is a viable treatment approach for performance anxiety in musicians.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 2018160     DOI: 10.1176/ajp.148.5.598

Source DB:  PubMed          Journal:  Am J Psychiatry        ISSN: 0002-953X            Impact factor:   18.112


  24 in total

1.  Stage fright: its experience as a problem and coping with it.

Authors:  Regina Studer; Patrick Gomez; Horst Hildebrandt; Marc Arial; Brigitta Danuser
Journal:  Int Arch Occup Environ Health       Date:  2011-01-06       Impact factor: 3.015

2.  Protective effect of propranolol and nadolol on social defeat-induced behavioral impairments in rats.

Authors:  Safiyya Zaidi; Fatin Atrooz; Daniel Valdez; Hesong Liu; Camila Kochi; Richard A Bond; Samina Salim
Journal:  Neurosci Lett       Date:  2020-03-09       Impact factor: 3.046

Review 3.  Social anxiety disorder: recent findings in the areas of epidemiology, etiology, and treatment.

Authors:  C Blanco; K Nissenson; M R Liebowitz
Journal:  Curr Psychiatry Rep       Date:  2001-08       Impact factor: 5.285

Review 4.  A risk-benefit assessment of buspirone in the treatment of anxiety disorders.

Authors:  J C Pecknold
Journal:  Drug Saf       Date:  1997-02       Impact factor: 5.606

5.  Acute effects of oxytocin in music performance anxiety: a crossover, randomized, placebo-controlled trial.

Authors:  Alini D V Sabino; Marcos Hortes N Chagas; Flávia L Osório
Journal:  Psychopharmacology (Berl)       Date:  2020-03-02       Impact factor: 4.530

6.  A placebo-controlled trial of phenelzine, cognitive behavioral group therapy, and their combination for social anxiety disorder.

Authors:  Carlos Blanco; Richard G Heimberg; Franklin R Schneier; David M Fresco; Henian Chen; Cynthia L Turk; Donna Vermes; Brigette A Erwin; Andrew B Schmidt; Harlan R Juster; Raphael Campeas; Michael R Liebowitz
Journal:  Arch Gen Psychiatry       Date:  2010-03

Review 7.  The neurobiology of social phobia: from pharmacotherapy to brain imaging.

Authors:  M Van Ameringen; C Mancini; P Farvolden; J Oakman
Journal:  Curr Psychiatry Rep       Date:  2000-08       Impact factor: 5.285

8.  Is it Beneficial to Add Pharmacotherapy to Cognitive-Behavioral Therapy when Treating Anxiety Disorders? A Meta-Analytic Review.

Authors:  Stefan G Hofmann; Alice T Sawyer; Kristina J Korte; Jasper A J Smits
Journal:  Int J Cogn Ther       Date:  2009-01-01

Review 9.  Canadian clinical practice guidelines for the management of anxiety, posttraumatic stress and obsessive-compulsive disorders.

Authors:  Martin A Katzman; Pierre Bleau; Pierre Blier; Pratap Chokka; Kevin Kjernisted; Michael Van Ameringen; Martin M Antony; Stéphane Bouchard; Alain Brunet; Martine Flament; Sophie Grigoriadis; Sandra Mendlowitz; Kieron O'Connor; Kiran Rabheru; Peggy M A Richter; Melisa Robichaud; John R Walker
Journal:  BMC Psychiatry       Date:  2014-07-02       Impact factor: 3.630

10.  Nonpharmacological treatments for anxiety disorders.

Authors:  Jean Cottraux
Journal:  Dialogues Clin Neurosci       Date:  2002-09       Impact factor: 5.986

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.